Invest KOREA

Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) said on Monday it will launch a panel next month to prepare for the establishment of an artificial intelligence (AI) center to support drug discovery and development in Korea.

The panel will be responsible for materializing the establishment plan over the next year.

The AI center project will be joined by Korea Health Industry Development Institute (KHIDI), Korea Conformity Laboratories and other stakeholders, KPBMA said. The panel will be headed by Dr. Lee Dong-ho, a professor at Asan Medical Center, who had led a drug development fund launched by the government in 2011 to support the industry’s R&D programs.

The pharmaceutical community expects artificial intelligence and big data analytics to bring significant productivity improvement in the process of drug discovery and development by optimizing study designs and predicting the mechanism of action and possible side effects of a treatment. This could raise the odds of a successful drug development program while saving R&D costs and time.


KPBMA Chairman Won Hee-mok

By Kim Hye-soon and Minu Kim

Copyrights Pulse by Maeil Business News Korea. All Rights Reserved.

Source: Pulse by Maeil Business News Korea (Dec. 19, 2017)